Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.

doi:10.1016/j.cllc.2025.12.005

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.

Clinical lung cancer - 1 Mar 2026

Tomasini Pascale, Juan-Vidal Oscar, Califano Raffaele, Lin Chien-Chung, Hulo Pauline, Dooms Christophe, Fang Jian, Blasco Ana, Kowalski Dariusz, Salinas Jorge, Babu Govind, Mun Tho Lye, Bearz Alessandra, Surmont Veerle, Baldotto Clarissa, Sharma Richu, Arrieta Oscar, Stencel Katarzyna, Card Cynthia, Zer Alona, Massarelli Erminia, Fang Bruno, Mashru Sandeep, Schuchard Julia, Sermon Jan, Diels Joris, Chu Pei-Ling, Withelder Monica, Bauml Joshua M, Shah Sujay, Baig Mahadi, Felip Enriqueta

Abstract excerpt

OBJECTIVE: The MARIPOSA-2 study demonstrated improved progression-free survival with amivantamab and chemotherapy compared with chemotherapy alone in patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer (NSCLC) with disease progression on or after treatment with osimertinib. This publication describes the results of patient-reported outcomes (PROs) measures and time to symptomatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Aniline Compounds

Share to Antineoplastic Combined Chemotherapy Protocols

Share to Carcinoma, Non-Small-Cell Lung

Share to Indoles

Share to Patient Reported Outcome Measures

Share to Pyrimidines

Share to Quality of Life

Source

Open in PubMed

Identifiers

PMID: 41544603
DOI: 10.1016/j.cllc.2025.12.005

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.PMID 41544603Read ↗

Patient-reported outcomes and time to symptomatic progression from PAPILLON: amivantamab plus chemotherapy vs chemotherapy as first-line treatment of EGFR exon 20 insertion-mutated advanced NSCLC.Semantic proximity Read ↗

Amivantamab plus chemotherapy versus chemotherapy for first-line treatment of participants with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer: PAPILLON Asia subgroup analysis.Semantic proximity Read ↗

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.Semantic proximity Read ↗

MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSASemantic proximity Read ↗

Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Efficacy of Mobocertinib and Amivantamab in Patients With Advanced Non-Small Cell Lung Cancer With EGFR Exon 20 Insertions Previously Treated With Platinum-Based Chemotherapy: An Indirect Treatment Comparison.Semantic proximity Read ↗

MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Safety and efficacy of concurrent radiation therapy with amivantamab in patients with advanced EGFR- or MET-altered non-small cell lung cancer.Semantic proximity Read ↗

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.Semantic proximity Read ↗

Osimertinib plus platinum-pemetrexed in newly diagnosed epidermal growth factor receptor mutation-positive advanced/metastatic non-small-cell lung cancer: safety run-in results from the FLAURA2 study.Semantic proximity Read ↗

Recent Advances in the Management of EGFR Mutated Advanced Non-Small Cell Lung Cancer-A Narrative ReviewSemantic proximity Read ↗

Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.